Methamphetamine: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [pending revision] |
MDElliottMD (talk | contribs) Pharmacopedia: add <pharmaInteractions/> |
MDElliottMD (talk | contribs) Migrate <indication> tags to <problem> (Phase 2 of indications-to-problems rebuild) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 17: | Line 17: | ||
| mechanism = Monoamine releasing agent — TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport | | mechanism = Monoamine releasing agent — TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport | ||
| intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States. | | intro = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States. | ||
| indications = < | | indications = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/> | ||
< | <problem slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/> | ||
| dosing = | effects = | | dosing = | effects = | ||
* <effect ref="attention" author="MDElliottMD"/> | * <effect ref="attention" author="MDElliottMD"/> | ||
| Line 62: | Line 62: | ||
}} | }} | ||
[[Category:Stimulants & Wake-Promoting Agents]] | |||
[[Category:Amphetamines]] | |||
[[Category:Psychostimulants]] | [[Category:Psychostimulants]] | ||
[[Category:Phenethylamines]] | |||